• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    DarioHealth to Report Second Quarter 2024 Results on Thursday, August 8th

    7/30/24 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care
    Get the next $DRIO alert in real time by email

    Company to host conference call and webcast at 8:30am ET

    NEW YORK, July 30, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2024, on Thursday, August 8th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time.

    DarioHealth Corp. Logo

    Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call.

    Conference Call Details

    Date: Thursday, August 8th, 8:30am ET

    Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)

    Call me™: https://emportal.ink/3V5ogDP

    Participants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to scheduled start time.

    Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1672806&tp_key=f245af335e

    Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through Sunday, September 8th, 2024. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1163410.

    About DarioHealth Corp.

    DarioHealth Corp. (NASDAQ:DRIO) is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. 

    Our user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and results.  Making the right thing to do the easy thing to do.

    Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers.  To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.

    Cautionary Note Regarding Forward-Looking Statements

    This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected date of its earnings release. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    DarioHealth Corporate Contact

    Mary Mooney

    VP Marketing

    mary@dariohealth.com

    +1-312-593-4280

    DarioHealth Investor Relations Contact

    Kat Parrella

    Investor Relations Manager

    [email protected]

    +315-378-6922

    Media Contact:

    Scott Stachowiak

    [email protected]

    +1-646-942-5630

    Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/dariohealth-to-report-second-quarter-2024-results-on-thursday-august-8th-302209732.html

    SOURCE DarioHealth Corp.

    Get the next $DRIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRIO

    DatePrice TargetRatingAnalyst
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    5/13/2022$8.75Neutral → Buy
    Alliance Global Partners
    1/26/2022$28.00 → $25.00Buy
    Aegis Capital
    8/19/2021$35.00 → $28.00Buy
    Aegis Capital
    More analyst ratings

    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      11/14/24 4:15:15 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      9/12/24 4:37:42 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Nelson Steven Charles bought $12,292 worth of shares (15,000 units at $0.82), increasing direct ownership by 60% to 40,000 units (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      9/10/24 6:00:13 AM ET
      $DRIO
      Medical/Dental Instruments
      Health Care

    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Franco-Yehuda Chen was granted 500,000 shares (SEC Form 4)

      4 - DarioHealth Corp. (0001533998) (Issuer)

      5/15/25 4:02:48 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Franco-Yehuda Chen

      3 - DarioHealth Corp. (0001533998) (Issuer)

      5/15/25 4:01:27 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care
    • New insider Leisure Lawrence B. claimed ownership of 258,000 shares (SEC Form 3)

      3 - DarioHealth Corp. (0001533998) (Issuer)

      3/7/25 4:05:19 PM ET
      $DRIO
      Medical/Dental Instruments
      Health Care